Literature DB >> 1907252

Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment.

C D Funk1, L B Funk, M E Kennedy, A S Pong, G A Fitzgerald.   

Abstract

Platelets metabolize arachidonic acid to thromboxane A2, a potent platelet aggregator and vasoconstrictor compound. The first step of this transformation is catalyzed by prostaglandin (PG) G/H synthase, a target site for nonsteroidal antiinflammatory drugs. We have isolated the cDNA for both human platelet and human erythroleukemia cell PGG/H synthase using the polymerase chain reaction and conventional screening procedures. The cDNA encoding the full-length protein was expressed in COS-M6 cells. Microsomal fractions from transfected cells produced prostaglandin endoperoxide-derived products which were inhibited by indomethacin and aspirin. Mutagenesis of the serine residue at position 529, the putative aspirin acetylation site, to an asparagine reduced cyclooxygenase activity to barely detectable levels, an effect observed previously with the expressed sheep vesicular gland enzyme. Platelet-derived growth factor and phorbol ester differentially regulated the expression of PGG/H synthase mRNA levels in the megakaryocytic/platelet-like HEL cell line. The PGG/H synthase gene was assigned to chromosome 9 by analysis of a human--hamster somatic hybrid DNA panel. The availability of platelet PGG/H synthase cDNA should enhance our understanding of the important structure/function domains of this protein and its gene regulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907252

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  64 in total

1.  Characterization of human 12-lipoxygenase genes.

Authors:  C D Funk; L B Funk; G A FitzGerald; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties.

Authors:  P F Moore; D L Larson; I G Otterness; A Weissman; S B Kadin; F J Sweeney; J D Eskra; A Nagahisa; M Sakakibara; T J Carty
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

3.  Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement.

Authors:  Nicole Dodge Zantek; Russell V Luepker; Sue Duval; Karen Miller; Niki Oldenburg; Alan T Hirsch
Journal:  Clin Appl Thromb Hemost       Date:  2013-05-07       Impact factor: 2.389

Review 4.  The second generation of COX-2 inhibitors: what advantages do the newest offer?

Authors:  Dirk O Stichtenoth; Jürgen C Frölich
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation.

Authors:  R S Smith; T J Smith; T M Blieden; R P Phipps
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

6.  Cyclooxygenase-1 and -2 are expressed by human T cells.

Authors:  J L Pablos; B Santiago; P E Carreira; M Galindo; J J Gomez-Reino
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

7.  Cyclo-oxygenase-2 inhibition increases blood pressure in rats.

Authors:  Klaus Höcherl; Dierk Endemann; Martin C Kammerl; Horst F Grobecker; Armin Kurtz
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 8.  [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase].

Authors:  D O Stichtenoth; H Zeidler; J C Frölich
Journal:  Med Klin (Munich)       Date:  1998-07-15

9.  Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F2-isoprostane formation.

Authors:  P Patrignani; G Santini; M R Panara; M G Sciulli; A Greco; M T Rotondo; M di Giamberardino; J Maclouf; G Ciabattoni; C Patrono
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 10.  Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.

Authors:  Jeffrey S Borer; Lee S Simon
Journal:  Arthritis Res Ther       Date:  2005-09-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.